Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Bio-Techne Corp (TECH)

A forensic read on Bio-Techne Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

B · Sound & dependable

Forensic grade

Safe

Financial health

8.2

Distress distance

Clean

Earnings quality

Forensic signals

9.0%

ROE

-0.4%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Bio-Techne Corp earns a B (Sound & dependable) forensic quality grade, and its balance-sheet distress test reads 8.2, placing it in the Safe zone. 2 forensic signals were flagged in its latest SEC filings, led by inventory days.

What the filings flag

169d

FY2025→FY2026

Inventory days. Days inventory outstanding moved from 157 to 169 FY2025→FY2026 (against cost of goods sold; inventory +3% vs -3% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.

8.7%

FY2026

Return on invested capital. Return on invested capital is 8.7% in the latest fiscal year, against 7.8% in FY2024, having run between 3.3% and 8.7% across FY2024–FY2026 with no direction held. After-tax operating profit was $186M in FY2024 and $190M in FY2026, with operating income at 17.8% of revenue in FY2024, 8.4% in FY2025 and 20.7% in FY2026. The capital base behind it went from $2.4B in FY2024 to $2.2B in FY2026 (-9%), while the revenue it carried went from $1.2B to $1.2B.

Key fundamentals

Latest Revenue$1.22B

Revenue Growth YoY-0.4%

Revenue CAGR (2yr)+2.4%

Net Margin15.0%

Free Cash Flow$263.2M

Return on Equity9.0%

Debt / Equity0.09x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Bio-Techne Corp's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.